Why Self-Medicating With Psilocybin Is Illegal in Australia
About one in three papers on psychedelic-assisted therapy I've read in the last year opens with some version of "growing public interest" , and honestly, the interest is real. So is the confusion. A lot of people read about promising early-phase research, hear about overseas access programmes, and quietly wonder whether they can sidestep the formal system. The short answer is no. The longer answer is what this piece is about.
Psilocybin's legal status in Australia
Psilocybin , the serotonergic compound found in certain fungi , is listed as a Schedule 9 Prohibited Substance under the Poisons Standard (the Commonwealth document that classifies drugs by risk and access). Schedule 9 is the most restrictive category. It covers substances considered to have no accepted therapeutic use outside of limited, tightly controlled research and clinical contexts. Possession, manufacture, supply, or use outside those contexts is a criminal offence under both Commonwealth and state/territory law.
That's the baseline. And it hasn't changed for most Australians, despite what some headlines imply.
What did change in February 2023 was specific and narrow: the Therapeutic Goods Administration (TGA) amended the Poisons Standard to allow Authorised Prescribers to prescribe psilocybin (reclassified to Schedule 8, a controlled drug, for this specific pathway) to eligible patients for treatment-resistant depression. MDMA received a parallel amendment for PTSD. This came into effect on 1 July 2023.
To be clear about what that means: a small number of psychiatrists registered as Authorised Prescribers under the TGA framework can now legally prescribe psilocybin to specific patients, under strict conditions. That is categorically different from personal possession or self-administration. Outside the Authorised Prescriber pathway, psilocybin remains Schedule 9. Obtaining, possessing, or using it without that prescription is still a criminal offence; full stop.
What "self-medicating" actually means in this context
Self-medicating with psilocybin typically refers to someone obtaining psilocybin-containing fungi or extracted compound outside a clinical setting and administering it to themselves, usually based on dosing information circulating online or in communities that follow certain research literature. Sometimes people describe this using the clinical language they've encountered, "microdosing", "macrodosing", specific gram-weights reported in studies.
I want to be careful here. I'm not going to reproduce or frame those reported amounts as a guide, because that's not what this piece is for, and more practically, it wouldn't be legal or safe to do so. What I will say is that any amount of psilocybin obtained outside the Authorised Prescriber pathway involves a prohibited substance, regardless of the quantity involved or the motivation behind it.
State and territory penalties vary, but possession of a prohibited substance can carry significant fines and imprisonment. In Western Australia, where I'm based, psilocybin possession is a serious criminal matter. The Australian Drug Foundation's publicly available resources confirm psilocybin's ongoing prohibited status and the associated legal consequences, I've linked to their resource below.
Why the research community's framing doesn't translate to personal use
This is the part that I think gets lost. Clinical research involving psilocybin in Australia operates under specific TGA-approved exemptions. Institutions apply for authorisation, ethics committees approve protocols, participants are screened extensively, a named compound of known purity is administered in a controlled environment, and clinicians monitor participants throughout. The research framing you see in journals; doses described in milligrams per kilogram, session structures, preparation periods, exists within that controlled infrastructure.
When someone reads a 2023 paper from a peer-reviewed journal reporting on a Phase 2 trial, the reported doses are describing what happened inside that framework. They are not instructions. They are not a protocol anyone outside that system is authorised to follow. And, this matters; the compounds used in trials are pharmaceutical-grade, tested, and known. Material obtained outside a clinical setting is none of those things. Purity, potency, contamination: none of it is verified. The pharmacokinetic profile of psilocybin can vary significantly depending on the source material, which is a real safety consideration entirely apart from the legal one. For more on how the body processes compounds like this, our pharmacokinetics glossary entry covers the fundamentals.
The Authorised Prescriber pathway, what it actually requires
The Authorised Prescriber scheme is a TGA mechanism that allows certain approved specialists to prescribe medicines not yet listed on the Australian Register of Therapeutic Goods (the ARTG) for specific patient populations. It is not a self-referral process. A patient cannot approach this pathway independently.
To access psilocybin under this scheme, a patient must be under the care of a psychiatrist who holds Authorised Prescriber status specifically for psilocybin, have a confirmed diagnosis of treatment-resistant depression (as defined by TGA criteria), and meet the clinical eligibility requirements set by the prescribing psychiatrist. The prescriber is responsible for the clinical decision, the monitoring, and the reporting obligations to the TGA. Sessions occur in approved clinical settings.
There is also the Special Access Scheme (SAS), a separate pathway for individual patient access to unapproved therapeutic goods, but again, this requires a registered medical practitioner to apply on behalf of a specific patient, not self-application.
Neither pathway is accessible to the general public without specialist medical involvement. I'd argue that some of the media coverage of the 2023 rescheduling significantly overstated how broadly accessible these pathways are in practice, and that's contributed to real confusion. The practical reality is that access remains limited, specialist-gated, and not analogous to a GP prescribing a standard Schedule 4 medication.
Serotonin receptors and what psilocybin actually does; briefly
A quick note on mechanism, because it's relevant to why unmonitored use carries specific risks. Psilocybin is a prodrug, the body converts it to psilocin, which binds primarily to 5-HT2A serotonin receptors in the brain. This is distinct from the endocannabinoid system, which governs much of the cannabis pharmacology we cover elsewhere on this site. The serotonergic mechanism produces the perceptual and psychological effects associated with the compound, and also carries specific contraindication risks, particularly for people with personal or family histories of psychosis or certain cardiovascular conditions, and for people taking other serotonergic medications.
I've been going back through some of the 2022–2024 trial literature between chess losses (I play online, badly), and even in controlled settings with screened populations, adverse psychological events are documented. Unmonitored, outside a clinical environment, with an unverified compound; the risk profile is not the same as what gets reported in peer-reviewed trial data. Anyone who implies otherwise is not reading the methods sections carefully enough.
The legal risk is real and not evenly distributed
One thing the research-forward coverage rarely discusses: the legal consequences of psilocybin possession fall disproportionately on people with less access to legal support, and a criminal record for a drug offence can affect employment, travel, and professional licensing in ways that are rarely reversible. The scientific discussion happening in journals and at conferences is happening in a context of legal privilege that most people engaging with that information don't share. I think that deserves to be said plainly.
If you're looking for information about the formal access pathways, what they require, who they currently apply to, the TGA's published guidance is the primary source. I've linked to it below.
The law is the law as it stands today. Research into psilocybin's mechanisms continues, regulatory frameworks may evolve, and none of that changes what is currently a criminal prohibition for the overwhelming majority of Australians.
Sources
- Scheduling delegate's final decisions: February 2023; Therapeutic Goods Administration (TGA)
- Magic mushrooms (psilocybin): drug facts, Australian Drug Foundation (ADF)
- Authorised prescribers: how the scheme works, Therapeutic Goods Administration (TGA)
- Psilocybin for treatment-resistant depression: trial design and safety monitoring; National Center for Biotechnology Information (NCBI/PubMed)
, Daniel Okoro, Psychedelic science & law writer
Common questions
- Is psilocybin legal in Australia?
- Psilocybin remains a Schedule 9 Prohibited Substance under the Poisons Standard for most Australians. Since 1 July 2023, TGA-registered Authorised Prescribers can legally prescribe psilocybin (under Schedule 8 conditions) to eligible patients with treatment-resistant depression, but outside that specific clinical pathway, possession and use is a criminal offence.
- Can I access psilocybin therapy through a GP in Australia?
- No. The Authorised Prescriber pathway for psilocybin requires a specialist psychiatrist with specific TGA authorisation. A general practitioner cannot prescribe psilocybin. Patients cannot self-refer into this pathway — it requires formal specialist diagnosis and clinical eligibility assessment.
- What are the legal consequences of possessing psilocybin in Australia?
- Penalties vary by state and territory but possession of a Schedule 9 prohibited substance is a serious criminal offence across all jurisdictions. Consequences can include significant fines and imprisonment. A criminal record for drug possession can also affect employment, professional licensing, and international travel.
- Does the 2023 TGA rescheduling mean psilocybin is now broadly available?
- No. The 2023 amendment created a narrow clinical pathway for Authorised Prescribers only. Psilocybin remains Schedule 9 (prohibited) for all uses outside that tightly controlled prescribing framework. The amendment did not decriminalise possession or create any form of general public access.
- Why is unmonitored psilocybin use considered risky beyond the legal issues?
- Psilocybin obtained outside clinical settings is of unknown purity and potency, which creates unpredictable pharmacokinetic effects. The compound also carries specific contraindications — including for people with personal or family histories of psychosis and those taking serotonergic medications — that are screened for carefully in clinical trials but cannot be assessed without specialist medical involvement.
Related reading
How Psilocybin Interacts With Serotonin (5-HT2A) ReceptorsHow psilocybin interacts with serotonin receptors: a plain-English look at psilocin, 5-HT2A binding and why Australian law still applies to all of it.
Contraindications Discussed in Clinical Psychedelic ResearchPsilocybin remains Schedule 9 in Australia outside specific AP pathways. Here's what clinical research says about contraindications — and why they matter.
DMT and Ayahuasca: Legal Status in AustraliaDMT and ayahuasca are Schedule 9 prohibited substances in Australia. Here's what the law actually says, and what the science describes.
Psilocin: The Active MetabolitePsilocin is the active metabolite behind psilocybin's pharmacological effects. Here's what the chemistry actually shows — and what Australian law says.
Microdosing: What the Term Means (and the Law in Australia)Microdosing is a term with a specific scientific meaning — and in Australia, psilocybin remains Schedule 9 prohibited outside tightly regulated clinical settings.
The 2023 Australian Down-Scheduling of PsilocybinAustralia's 2023 psilocybin rescheduling created a narrow legal pathway under the TGA. Here's what actually changed — and what didn't.
I write our psychedelic-science and regulation pieces, which means being very precise about what the law actually allows. Trained in neuroscience comms. I play jazz piano poorly but happily, lose at chess online, and read too many papers.
BSc Neuroscience
More from Daniel Okoro
- The 2023 Australian Down-Scheduling of PsilocybinAustralia's 2023 psilocybin rescheduling created a narrow legal pathway under the TGA. Here's what actually changed — and what didn't.
Psychedelics and Drug Interactions (Educational)Psilocybin remains Schedule 9 prohibited in Australia outside narrow AP pathways. Here's what the research says about psychedelics and drug interactions.
Psychedelic-Assisted Therapy: The Supervised Clinical ModelPsilocybin remains a Schedule 9 prohibited substance in Australia outside a narrow clinical pathway. Here's what the supervised model actually looks like.
MDMA-Assisted Therapy and Its Australian Regulatory StatusMDMA sits at Schedule 8 in Australia under a narrow 2023 TGA ruling. Here's what that actually means legally, and what the research says.
Ketamine in Medicine: Regulatory and Clinical ContextKetamine sits in a legally complex space in Australia — Schedule 8 controlled drug in medicine, with a growing research profile. Here's what the regulation actually says.
The Authorised Prescriber Pathway for PsilocybinPsilocybin remains Schedule 9 prohibited in Australia — but the Authorised Prescriber pathway created a narrow legal route in 2023. Here's how it works.